ISK Ltd is a resident company of Johnson & Johnson Innovation – JLABS, a premier life science incubator program.
JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world.  As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers

ISK is proud to announce a significant development in our ongoing commitment to cancer research and treatment. We have successfully developed and are now in the process of filing a patent for an enhanced form of Nerofe, our proprietary cancer treatment.

This advancement represents a major milestone in our mission to combat cancer. The enhanced form of Nerofe has shown promising potential in preclinical studies, demonstrating our continuous innovation in the field of oncology.

We remain dedicated to our mission of improving patient outcomes and will continue to share updates on the progress of this exciting development. Thank you for your continued support.

ISK is excited to report the official opening of its second FDA approved clinical trial in the US in patients with pancreatic cancer and metastatic colorectal cancer at Georgetown University in Washington, D.C.

Following FDA approval to open our trial at Georgetown University in Washington DC, we received final IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track

Using a new formulation of Nerofe, treating a patient with Stage 4 squamous cell lung cancer (positive for ST2), caused the complete disappearance of some tumors and a decrease in the size of other tumors. Increase in hepatic function.